AERI - Dividend announcements

Leveraging Alcon's robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Alcon's presence in the $20 billion global ophthalmic pharmaceutical category1 Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has completed its acquisition of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI, "Aerie"))). This transaction helps bolster Alcon's presence in the ophthalmic pharmaceutical space with its growing portfolio of commercial products and development pi

Builds on Alcon's existing commercial expertise in the estimated $20 billion global ophthalmic pharmaceutical segment1 Adds Rocklatan® and Rhopressa®, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates Transaction values Aerie at approximately $770 million in equity value and is expected to be accretive to Alcon's core diluted EPS in 2024 Ad hoc announcement pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and Aerie Pharmaceuticals, Inc. (NASDAQ:AERI, "Aerie"))), a pharmaceutical company focused on the discovery, development, manufacturing and commercialization of first-in